NEW YORK, NY / ACCESSWIRE / January 4, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Iovance Biotherapeutics, Inc. ("Iovance") (NASDAQ:IOVA) concerning possible violations of federal securities laws.
On December 27, 2023, Iovance announced that, on December 22, 2023, the U.S. Food and Drug Administration ("FDA") had placed a clinical hold on the Company's IOV-LUN-202 trial, which was investigating the Iovance's lead product candidate for the treatment of metastatic non-small cell lung cancer. Iovance advised that the FDA's decision to place the clinical hold was "in response to a recently reported Grade 5 (fatal) serious adverse event potentially related to the non-myeloablative lymphodepletion pre-conditioning regimen." On this news, Iovance's stock price fell 18.67% to close at $7.23 per share on December 27, 2023. To obtain additional information, go to:
https://zlk.com/pslra-1/iovance-lawsuit-submission-form?prid=62372&wire=1
or contact Joseph E. Levi, Esq. either via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500.
WHY LEVI & KORSINSKY: Over the past 20 years, Levi & Korsinsky LLP has established itself as a nationally-recognized securities litigation firm that has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. The firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States. Attorney Advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 17th Floor
New York, NY 10004
jlevi@levikorsinsky.com
Tel: (212)363-7500
Fax: (212)363-7171
https://zlk.com/
SOURCE: Levi & Korsinsky, LLP
View the original
press release on accesswire.com
